OBJECTIVE -A relationship between inflammation, measured by C-reactive protein (CRP), and forced vital capacity (FVC) in diabetes or metabolic syndrome (MetS) has not been established. We investigated whether high CRP is related to reduced FVC in MetS and diabetes.
C
ross-sectional (1,2) and prospective (3) studies have demonstrated impaired lung function in individuals with diabetes and metabolic syndrome (MetS). Recent studies show that reduced lung function may be a precursor of diabetes (4). People with reduced lung function have greater levels of inflammation (5), and people with diabetes or MetS (6,7), including those with elevated C-reactive protein (CRP) (8) , are at increased risk of cardiovascular disease. Although the interplay among MetS, diabetes, and insulin resistance has been thoroughly investigated and extensively published, their role in systemic inflammation and lung function impairment has not been firmly established. We examined whether increased levels of CRP may help identify lung function impairment in individuals with MetS/diabetes.
RESEARCH DESIGN AND
METHODS -Using data from the Third National Health and Nutrition Examination Survey (NHANES III), 1988 -1994 (9), we examined adults aged 18 -79 years (n ϭ 4,272 projected to 43.2 million, 59.7% female) with available forced vital capacity (FVC) data, who were nonsmokers, absent of pulmonary obstructions, and without known pulmonary disease. Spirometric data were obtained using a spirometry system following the modified 1987 procedures of the National Institute for Occupational Safety and Health (NIOSH) and American Thoracic Society (ATS). Predicted FVC was calculated using equations developed by Hankinson et al. (10) . CRP was measured using a latex-enhanced nephelometry technique, providing a lowest detectable concentration of 2.1 mg/l. Additional details of the NHANES methodology have been published (9) .
MetS was defined by the presence of at least three of the following: 1) waist circumference Ͼ102 cm for men and Ͼ88 cm for women, 2) triglyceride level Ն150 mg/dl if fasting, 3) HDL cholesterol level Ͻ40 mg/dl for men or Ͻ50 mg/dl for women, 4) blood pressure Ն130/85 mmHg or on antihypertensive medications, and 5) fasting glucose level 100 -125 mg/dl (7.0 mmol/l) according established criteria (11) . Diabetes was defined by a fasting glucose Ն126 mg/dl (or Ն200 mg/dl if nonfasting), taking oral diabetes medication or insulin, or selfreport. CRP cut points were defined as normal (Յ3 mg/l) or high (Ͼ3 mg/l) based on established recommendations (12) . The 2 test of proportions or ANOVA was used to compare baseline characteristics among FVC groups. Multivariable logistic regression was used to examine the likelihood of decreased FVC (Ͻ80% of predicted) in those with MetS or diabetes by CRP group compared with those with neither of these conditions and low CRP, adjusted for age, sex, and ethnicity. SAS version 9.1.3 (SAS institute, Cary, NC) and SUDAAN version 9.0.1 (Research Triangle Institute, Research Triangle Park, NC) were used for analysis and computation of weighted estimates for projection to the U.S. population.
RESULTS -Individuals in FVC quartile 1 (lowest FVC) exhibited the highest CRP levels (P Ͻ 0.01). Additionally, individuals in FVC quartile 1 had higher triglycerides, glucose, systolic blood pressure, and HDL cholesterol than those in FVC quartile 4 (highest FVC) (P Ͻ 0.05). Prevalence of MetS was highest among individuals in FVC quartile 1
(24.7%) compared with those in FVC quartile 4 (11.5%) (P Ͻ 0.01). There were no significant differences in waist circumference, BMI, and sex across quartiles of FVC.
Predicted mean FVC values, adjusted for age, sex, and ethnicity, were significantly lower in those with high versus normal CRP levels among individuals with MetS (P Ͻ 0.01). FVC in those with MetS and high CRP (95.7%) was notably lower than in those with MetS and normal CRP (98.5%) (P Ͻ 0.01) and those with no MetS/diabetes and normal CRP (101.7%) (P Ͻ 0.01). Individuals with diabetes and high CRP had the lowest FVC (93.7%), significantly lower compared with those with no MetS/diabetes and normal CRP (101.7%) (P Ͻ 0.01).
When Recent prospective studies suggest reduced FVC to be a precursor of diabetes and MetS (5). It is not clear why reduced FVC occurs in people with diabetes and MetS, although several possible explanations have been suggested. First, in studies involving the alteration in alveolar wall and capillaries, with subsequent lung elastic recoil and carbon monoxide diffusion tests, there were no significant differences between insulin-dependent subjects with diabetes and healthy nonsmokers (13); however, other studies show a relationship (14) . Second, while hypoxemia could reduce FVC in diabetes and MetS, mildly reduced FVC is unlikely to be associated with significant hypoxemia (5). Third, inflammation has been shown to promote impaired lung function. CRP is an acute-phase protein that is produced by the liver under the influence of cytokines. These cytokines are produced at several extrahepatic sites, including the heart, vessel wall, and adipose tissues. Increased CRP levels have been described in people with diabetes, MetS, obesity, and inflammation (15) .
Limitations of this study include its cross-sectional design; it is uncertain whether the inflammatory process actually led to reduced FVC in those with MetS and diabetes. An important strength is the large sample and weighting, allowing findings to be generalized to the U.S. adult population. Moreover, the standardized measurement of lung function and other laboratory measurements, in- 
